Beyond Assessment of Quality of Life in Schizophrenia
Editat de A. George Awad, Lakshmi N.P. Vorugantien Limba Engleză Paperback – 31 mai 2018
Internationally renowned experts from different scientific backgrounds and scopes of expertise each make arguments for the need to invigorate quality of life as a concept in schizophrenia, by broadening its usefulness for clinical and research efforts. The book represents an important addition to the extensive contributions of its editors, Dr. A. George Awad and Dr. Lakshmi N.P. Voruganti, to the field of quality of life.
| Toate formatele și edițiile | Preț | Express |
|---|---|---|
| Paperback (1) | 338.47 lei 38-44 zile | |
| Springer International Publishing – 31 mai 2018 | 338.47 lei 38-44 zile | |
| Hardback (1) | 355.19 lei 38-44 zile | |
| Springer International Publishing – 27 iun 2016 | 355.19 lei 38-44 zile |
Preț: 338.47 lei
Preț vechi: 356.29 lei
-5% Nou
Puncte Express: 508
Preț estimativ în valută:
64.77€ • 67.93$ • 54.01£
64.77€ • 67.93$ • 54.01£
Carte tipărită la comandă
Livrare economică 03-09 ianuarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9783319807157
ISBN-10: 3319807153
Pagini: 224
Ilustrații: XIII, 224 p. 12 illus., 6 illus. in color.
Dimensiuni: 155 x 235 mm
Greutate: 0.36 kg
Ediția:Softcover reprint of the original 1st ed. 2016
Editura: Springer International Publishing
Colecția Adis
Locul publicării:Cham, Switzerland
ISBN-10: 3319807153
Pagini: 224
Ilustrații: XIII, 224 p. 12 illus., 6 illus. in color.
Dimensiuni: 155 x 235 mm
Greutate: 0.36 kg
Ediția:Softcover reprint of the original 1st ed. 2016
Editura: Springer International Publishing
Colecția Adis
Locul publicării:Cham, Switzerland
V-ar putea interesa
-
5-Hydroxytryptamine in Psychiatry: A Spectrum of IdeasMerton Sandler-25%Preț: 957.97 lei1269.37 lei -
The Pharmacology of LSDAnnelie Hintzen-15%Preț: 516.61 lei606.44 lei -
Preț: 260.93 lei -
-5%Preț: 365.85 lei385.11 lei -
Stahl's Illustrated Anxiety, Stress, and PTSDStephen M. Stahl-5%Preț: 366.08 lei385.35 lei -
Brain Drug Targeting: The Future of Brain Drug DevelopmentWilliam M. Pardridge-5%Preț: 363.99 lei383.16 lei -
-5%Preț: 598.29 lei629.78 lei -
Principles of Psychiatric GeneticsJohn I. Nurnberger, Jr MD-5%Preț: 1088.30 lei1145.58 lei -
-5%Preț: 620.55 lei653.21 lei -
Neuropsychopharmacology and TherapeuticsIS Ebenezer-5%Preț: 478.04 lei503.20 lei -
-5%Preț: 246.98 lei259.98 lei -
Current SchizophreniaMartin Lambert-5%Preț: 350.09 lei368.52 lei -
A Clinician’s Guide to ADHDJoseph Sadek-5%Preț: 620.57 lei653.24 lei -
-5%Preț: 832.17 lei875.96 lei -
-5%Preț: 1008.40 lei1061.48 lei
Cuprins
Part I:Basic and Conceptual Issues.- Schizophrenia and it’s sequelae.- Issues that slowed progress in the assessment of health-related quality of life in schizophrenia.- Social cognition and health-related quality of life in schizophrenia.- Conceptual issues in cultural adaptation and the role of culture in assessment of health-related quality of life in schizophrenia.- Part II:Methodological Issues.- A review of quality of life assessment measures in schizophrenia – limitations and future developments – a review.- Assessment of burden of care and quality of life of caregivers in schizophrenia.- Electronic technology and advances in assessment of outcomes.- Modern psychometric approaches to analysis of scales for health-related quality of life.- Part III:Beyond Assessment of Quality of Life in Schizophrenia.- Health-related quality of life as an outcome and mediator of other outcomes.- Using routine quality of life assessment to improve effectiveness of community mental health care.- Quality of life assessments in the development and clinical trials of new antipsychotics – pharmaceutical industry perspective.- Quality of life and health-costs – the feasibility of cost-utility analysis in schizophrenia.- Health-related quality of life in schizophrenia: health policy and resource allocation.- Beyond assessment of quality of life in schizophrenia: cultural, clinical and research perspectives from India – a case study.- Part IV:Reinventing Quality of Life in Schizophrenia.- Concluding remarks and future challenges.
Recenzii
“The purpose is to advocate for refining conceptually the idea of quality of life in schizophrenia, bridging the present gaps and going beyond measurements to its significant applications in impacting clinical care and health economics. … It is relevant for researchers evaluating treatment efficacy in terms of quality of life changes and clinicians who need to look beyond symptom reduction and how treatment affects the life of these individuals.” (Michael Easton, Doody's Book Reviews, November, 2016)
Notă biografică
Dr. A. George Awad is a professor emeritus in the Department of Psychiatry and the Institute of Medical Science, University of Toronto, Canada. Until recently, Dr. Awad served as the Founding President of the International Society of CNS Clinical Trials Methodology, and also as the Psychiatrist-in-Chief of Humber River Hospital, in Toronto. He is the recipient of numerous awards, including the Canadian College of Neuropsychopharmacology Medal for meritorious contributions to neuropsychopharmacology, the Joey and Toby Tanenbaum Award for distinguished researcher in schizophrenia, and, recently, the Andrew C. Leon Distinguished Career Award in CNS clinical trial methodology and neurosciences. Over his forty-five years of academic and research contributions, Dr. Awad dedicated his research focus on the “person” behind the illness and the outcomes that matter most to the patient.
Dr. Lakshmi N.P. Voruganti joined Dr. Awad as both a Master’s and PhD candidate, and made significant contributions exploring and extending Dr. Awad’s early research contributions, particularly in the area of neurobiology of subjective tolerability to antipsychotic medications. After gaining his PhD degree, he pursued an independent clinical research career as an associate professor at the University of Western Ontario, London, Ontario, Canada and, later, at McMaster’s University in Hamilton, Ontario. At present, he is a practicing psychiatrist at Oakville-Trafalgar Memorial Hospital in Oakville, Ontario, Canada.
Dr. Lakshmi N.P. Voruganti joined Dr. Awad as both a Master’s and PhD candidate, and made significant contributions exploring and extending Dr. Awad’s early research contributions, particularly in the area of neurobiology of subjective tolerability to antipsychotic medications. After gaining his PhD degree, he pursued an independent clinical research career as an associate professor at the University of Western Ontario, London, Ontario, Canada and, later, at McMaster’s University in Hamilton, Ontario. At present, he is a practicing psychiatrist at Oakville-Trafalgar Memorial Hospital in Oakville, Ontario, Canada.
Textul de pe ultima copertă
This book fills a significant research gap in how to integrate quality of life data into relevant clinical care plans, and to broaden its applicability to pharmacoeconomic studies of antipsychotic medications and health policy decision-making. It also presents an argument for reformulating the concept of health-related quality of life in schizophrenia as a bio-psycho-social construct, which provides an opportunity to better explore the many factors underpinning the concept itself.
Internationally renowned experts from different scientific backgrounds and scopes of expertise each make arguments for the need to invigorate quality of life as a concept in schizophrenia, by broadening its usefulness for clinical and research efforts. The book represents an important addition to the extensive contributions of its editors, Dr. A. George Awad and Dr. Lakshmi N.P. Voruganti, to the field of quality of life.
Caracteristici
Redefines the concept of quality of life in schizophrenia as a bio-psycho-social construct to provide the reader with a novel contextual understanding Examines the rapid advances in electronic technology as new approaches for assessment of patient-centered outcomes to update the reader on new techniques Critically reviews measurement tools and introduces new and modern approaches for scale development